# Patent

## Title
Substituted β-carbolines

## Abstract

The subject matter of the present invention is directed to novel substituted β-carbolines, and specifically compounds of the formula I,




which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of IκB kinase is involved.

## Background
This application is a continuation of application Ser. no. 10/627,978, filed on Jul. 28, 2003 (now U.S. Pat. No. 7,026,331), the entire contents of which are incorporated by reference herein; which is a continuation of application Ser. no. 09/812,785, filed on Mar. 15, 2001, now U.S. Pat. No. 6,627,637, and which claims priority benefit under 35 U.S.C. § 119 to EP application no. 00105514.4, filed Mar. 15, 2000, and to EP application no. 00125169.3, filed Nov. 18, 2000, the contents of which were incorporated by reference therein.


The present invention relates to novel substituted beta-carbolines, a process for their preparation and use thereof as pharmaceuticals.
Art related to the present invention includes U.S. Pat. Nos. 4,631,149 and 5,604,236. U.S. Pat. No. 4,631,149 discloses beta-carbolines useful as antiviral, antibacterial and antitumor agents. U.S. Pat. No. 5,604,236 discloses beta-carboline derivatives containing an acidic group, useful as thromboxane syntheses inhibitors.
NFkB is a heterodimeric transcription factor which can activate a large number of genes which code, inter alia, for proinflammatory cytokines such as IL-1, IL-2, TNFα or IL-6. NFkB is present in the cytosol of cells, building a complex with its naturally occurring inhibitor IkB. The stimulation of cells, for example by cytokines, leads to the phosphorylation and subsequent proteolytic degradation of IkB. This proteolytic degradation leads to the activation of NFkB, which subsequently migrates into the nucleus of the cell and there activates a large number of proinflammatory genes.
In disorders such as rheumatoid arthritis (in the case of inflammation), osteoarthritis, asthma, cardiac infarct, Alzheimer's disease or atherosclerosis, NFkB is activated beyond the normal extent. Inhibition of NFkB is also of benefit in cancer therapy, since it is employed there for the reinforcement of the cytostatic therapy. It has been shown that pharmaceuticals such as glucocorticoids, salicylates or gold salts, which are employed in rheumatic therapy, intervene in an inhibitory manner at various points in the NFkB-activating signal chain or interfere directly with the transcription of the genes.
The first step in the signal cascade mentioned is the degradation of IkB. This phosphorylation is regulated by the specific IkB kinase. To date, no inhibitors are known which specifically inhibit IkB kinase.
In the attempt to obtain active compounds for the treatment of rheumatoid arthritis (in the case of inflammation), osteoarthritis, asthma, cardiac infarct, Alzheimer's disease, carcinomatous disorders (potentiation of cytotoxic therapies) or atherosclerosis, the inventors have surprisingly discovered that the benzimidazoles of the present invention are strong and very specific inhibitors of IkB kinase.
The invention therefore relates to the compounds of the formula I




and/or a stereoisomeric form of the compounds of the formula I and/or a physiologically tolerable salt of the compounds of the formula I,

where B6, B7, B8 and B9 are independently selected from the group consisting of carbon atom and nitrogen atom, where B6, B7, B8 and B9 together comprise no more than two nitrogen atoms; wherein

    in case a)
    
        the substituents R1, R2 and R3 may be independently chosen from:
        1.1. hydrogen atom,
        1.2. halogen,
        1.3. —CN,
        1.4. —COOH,
        1.5. —NO2,
        1.6. —NH2,
        1.7. —O—(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from:
        
            1.7.1 phenyl, which is unsubstituted or mono- to penta-substituted by substituents independently chosen from halogen or —O—(C1-C4)-alkyl,
            1.7.2 halogen,
            1.7.3 —NH2,
            1.7.4 —OH,
            1.7.5 —COOR16, wherein R16 is hydrogen atom or —(C1-C10)-alkyl,
            1.7.6 —NO2,
            1.7.7 —S(O)—R14, wherein y is zero, 1 or 2, R14 is —(C1-C10)-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those defined under 1.7.1 to 1.7.11, amino or —N(R13)2,
            
                wherein R13 is independently of one another chosen from hydrogen atom, phenyl, —(C1-C10)-alkyl, —C(O)—(C1-C7)-alkyl, —C(O)-phenyl, —C(O)—NH—(C1-C7)-alkyl, —C(O)—O-phenyl, —C(O)—NH-phenyl, —C(O)—O—(C1-C7)-alkyl,
                —S(O)—R14, wherein R14 and y are as defined above,
                and wherein the R13 alkyl or phenyl groups in each case are unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or
                R13 together with the nitrogen atom to which it is bonded may be independently chosen to form a heterocycle having 5 to 7 ring atoms,
            
            
            1.7.8 —O-phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted independently of one another as defined under 1.7.1 to 1.7.11,
            1.7.9 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,
            1.7.10 —(C3-C7)-cycloalkyl or
            1.7.11 ═O,
        
        
        1.8. —N(R13)2, wherein R13 is as defined in 1.7.7 above,
        1.9. —NH—C(O)—R15, wherein R15 is
        
            1.9.1 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,
            
                wherein said radical is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, by —CF3, by benzyl or by —(C1-C10)-alkyl, wherein the —(C1-C10)-alkyl is mono to tri-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,
            
            
            1.9.2 —(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above or by —O—(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,
            1.9.3 —(C3-C7)-cycloalkyl,
            1.9.4 —N(R13)2, wherein R13 is as defined in 1.7.7 above, or
            1.9.5 phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, by —O—(C1-C10)-alkyl, by —CN, by —CF3, by —(C1-C10)-alkyl, wherein alkyl is mono to tri-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, or by two substituents of said phenyl which form a dioxolan ring,
        
        
        1.10. —S(O)y—R14, wherein R14 and y are as defined in 1.7.7 above,
        1.11. —C(O)—R12, wherein R12 is phenyl or —(C1-C7)-alkyl, wherein alkyl or phenyl are unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,
        1.12. —C(O)—O—R12, wherein R12 is as defined in 1.11. above,
        1.13. —(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,
        1.14. —O—(C1-C6)-alkyl-O—(C1-C6)-alkyl,
        1.15. —O—(C0-C4)-alkyl-(C3-C7)-cycloalkyl,
        1.16. —(C1-C4)-alkyl-N(R13)2, wherein R13 is as defined in 1.7.7 above
        1.17. —CF3 or
        1.18. —CF2—CF3,
    
    
    R4 is 1. —(C1-C10)-alkyl, wherein alkyl is mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,
    
        2. —CF3,
        3. —CF2—CF3,
        4. —CN,
        5. —S(O)y—R14, wherein R14 and y are as defined in 1.7.7 above,
        6. —NH2,
        7. —O—(C1-C10)-alkyl, wherein alkyl is mono- to penta-substituted by substituents independently chosen from
        
            7.1 phenyl, which is unsubstituted or mono- to penta-substituted by substituents independently chosen from halogen or —O—(C1-C4)-alkyl,
            7.2 halogen,
            7.3 —NH2,
            7.4 —OH,
            7.5 —COOR16, wherein R16 is hydrogen atom or —(C1-C10)-alkyl,
            7.6 —NO2,
            7.7 —S(O)—R14, wherein y is zero, 1 or 2, R14 is —(C1-C10)-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, amino or —N(R13)2,
            
                wherein R13 is independently of one another chosen from hydrogen atom, phenyl, —(C1-C10)-alkyl, —C(O)—(C1-C7)-alkyl, —C(O)-phenyl, —C(O)—NH—(C1-C7)-alkyl, —C(O)—O-phenyl, —C(O)—NH-phenyl, —C(O)—O—(C1-C7)-alkyl, —S(O)y—R14, wherein R14 and y are defined as in 7.7,
                and wherein the R13 alkyl or phenyl groups in each case are unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, or
                R13 together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,
            
            
            7.8 —O-phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,
            7.9 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, thiophene, 2-isoxazoline, isothiazolidine, 2-isothiazoline, or thiomorpholine,
            7.10 —(C3-C7)-cycloalkyl or
            7.11 ═O,
        
        
        8. —N(R17)2, wherein R17 is independently of one another chosen from hydrogen atom, phenyl, —(C1-C10)-alkyl, —C(O)-phenyl, —C(O)—NH—(C1-C7)-alkyl, —C(O)—(C1-C10)-alkyl, —C(O)—O-phenyl, —C(O)—NH-phenyl, —C(O)—O—(C1-C7)-alkyl, —S(O)y—R14, wherein R14 and y are as defined as in 7.7 above,
        
            and wherein alkyl or phenyl in each case are unsubstituted or mono- to penta-substituted independently of one another as defined under 1.7.1 to 1.7.11 above, or
            R17 together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,
        
        
        9. —NH—C(O)—R15, wherein R15 is
        
            9.1 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,
            
                wherein said radical is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, —CF3, benzyl or by —(C1-C10)-alkyl, wherein alkyl is mono to tri-substituted by substituents independently chosen from those as, defined under 1.7.1 to 1.7.11 above,
            
            
            9.2 —(C1-C10)-alkyl, wherein alkyl is mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above or by —O—(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,
            9.3 —(C3-C7)-cycloalkyl,
            9.4 —N(R13)2, wherein R13 is as defined in 1.7.7 above provided that
            
                —N(R13)2 is not —NH2, or
            
            
            9.5 phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, by —O—(C1-C10)-alkyl, by —CN, by —CF3, by —(C1-C10)-alkyl, wherein alkyl is mono to tri-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, or by two substituents of the phenyl radical which form a dioxolan ring
        
        
        10. —C(O)—R12, wherein R12 is phenyl or —(C1-C7)-alkyl, wherein phenyl or alkyl are mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,
        11. —C(O)—O—R12, wherein R12 is as defined in 10, above,
        12. —O—(C1-C6)-alkyl-O—(C1-C6)-alkyl,
        13. —O—(C0-C4)-alkyl-(C3-C7)-cycloalkyl or
        14. —(C1-C4)-alkyl-N(R13)2, wherein R13 is as defined in 1.7.7 above,
    
    
    R5 is 1. a hydrogen atom,
    
        2. —(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.4 above,
        3. —C(O)—R9, wherein R9 is
        
            —NH2, —(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.4, or —N(R13)2, wherein R13 is as defined in 1.7.7 above, or
        
        
        4. —S(O)2—R9, wherein R9 is as defined in 3. above, or
    
    
    R4 and R5 together with the atom to which they are bonded form a heterocycle, or
    R3 and R5 together with the atom to which they are bonded form a heterocycle containing an additional oxygen atom in the ring and
    R6, R7 and R8 independently of one another are chosen from hydrogen atom or methyl, or
    in case b)
    
        the substituents R1, R2 and R4 may be independently chosen as defined under 1.1 to 1.18 in case a) above,
    
    
    R3 is 1. —CF3,
    
        2. —CF2—CF3,
        3. —CN,
        4. —COOH,
        5. —NO2,
        6. —NH2,
        7. —O—(C1-C10)-alkyl, wherein alkyl is mono- to penta substituted by substituents independently chosen from
        
            7.1 phenyl, which is unsubstituted or mono- to penta-substituted by substituents independently chosen from halogen or —O—(C1-C4)-alkyl,
            7.2 halogen,
            7.3 —NH2,
            7.4 —OH,
            7.5 —COOR16, wherein R16 is hydrogen atom or —(C1-C10)-alkyl,
            7.6 —NO2,
            7.7 —S(O)—R14, wherein y is zero, 1 or 2, R14 is —(C1-C10)-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, amino or —N(R13)2,
            
                wherein R13 is independently of one another chosen from hydrogen atom, phenyl, —(C1-C10)-alkyl, —C(O)—(C1-C7)-alkyl, —C(O)-phenyl, —C(O)—NH—(C1-C7)-alkyl, —C(O)—O-phenyl, —C(O)—NH-phenyl, —C(O)—O—(C1-C7)-alkyl, —S(O)y—R14, wherein R14 and y are defined as in 7.7,
                and wherein the R13 alkyl or phenyl groups in each case are unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, or
                R13 together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,
            
            
            7.8 —O-phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,
            7.9 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,
            7.10 —(C3-C7)-cycloalkyl or
            7.11 ═O,
        
        
        8. —N(R13)2, wherein R13 is as defined in 1.7.7 above,
        9. —NH—C(O)—R15, wherein R15 is
        
            9.1 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,
            
                wherein said radical is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, —CF3, benzyl or by —(C1-C10)-alkyl, wherein alkyl is mono to tri-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,
            
            
            9.2 —(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above or by —O—(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,
            9.3 —(C3-C7)-cycloalkyl,
            9.4 —N(R13)2, wherein R13 is as defined in 1.7.7 above, or
            9.5 phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, by —O—(C1-C10)-alkyl, by —CN, by —CF3, by —(C1-C10)-alkyl, wherein alkyl is mono to tri-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, or by two substituents of the phenyl radical which form a dioxolan ring
        
        
        10. —S(O)y—R14, wherein R14 and y are as defined in 1.7.7 above,
        11. —C(O)—R12, wherein R12 is phenyl or —(C1-C7)-alkyl, wherein phenyl or alkyl are unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,
        12. —C(O)—O—R12, wherein R12 is as defined in 11. above,
        13. —(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,
        14. —O—(C1-C6)-alkyl-O—(C1-C6)-alkyl,
        15. —O—(C0-C4)-alkyl-(C3-C7)-cycloalkyl or
        16. —(C1-C4)-alkyl-N(R13)2, wherein R13 is as defined in 1.7.7 above,
    
    
    R5 is as defined as R5 in case a) above,
    R6, R7 and R8 independently of one another are chosen from hydrogen atom or methyl.

Examples include compounds of formula I, wherein in case a)

    B6, B7, B8, and B9 are each a carbon atom,
    R1, R2 and R3 independently of one another are chosen from hydrogen atom, halogen, cyano, nitro, amino, —O—(C1-C7)-alkyl, wherein alkyl is unsubstituted or substituted by phenyl, —CF2—CF3, —CF3, —N(R18)2,
    
        wherein R18 is independently of one another chosen from hydrogen atom, —(C1-C7)-alkyl, phenyl, —C(O)-phenyl, —C(O)-pyridyl, —C(O)—NH-phenyl, —C(O)—O-phenyl, —C(O)—O—(C1-C4)-alkyl or —C(O)—(C1-C7)-alkyl, wherein alkyl, pyridyl or phenyl are unsubstituted or mono- to tri-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or R18 together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,
    
    
     S(O)y—R14,
    
        wherein y is zero, 1 or 2, and R14 is —(C1-C10)-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, amino or —N(R18)2,
        wherein R18 is as defined above,
        wherein alkyl is unsubstituted or mono- to tri-substituted independently of one another as defined under 1.7.1 to 1.7.11, or
    
    
     —C(O)—O—R2, wherein R12 is as defined as in 1.11 above,
    R4 is cyano, amino, —O—(C1-C7)-alkyl, wherein alkyl is substituted by phenyl;
    
        —CF2—CF3, —CF3, —N(R18)2,
        
            wherein R18 is independently of one another chosen from hydrogen atom, —(C1-C7)-alkyl, phenyl, —C(O)-phenyl, —C(O)-pyridyl, —C(O)—NH-phenyl, —C(O)—O-phenyl, —C(O)—O—(C1-C4)-alkyl or —C(O)—(C1-C7)-alkyl, wherein each alkyl, pyridyl or phenyl are unsubstituted or mono- to tri-substituted independently of one another as defined under 1.7.1 to 1.7.11, or R18 together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,
        
        
        S(O)y—R14,
        
            wherein y is zero, 1 or 2, and R14 is —(C1-C10)-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, amino or —N(R18)2,
            wherein R18 is as defined above,
            wherein alkyl is unsubstituted or mono- to tri-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or
        
        
        —C(O)—O—R12, wherein R12 is as defined above,
    
    
    R6, R7 and R8 independently of one another are chosen from hydrogen atom or methyl, and
    R5 is as defined as for case a) above,
    or in case b)
    
        the substituents R1, R2 and R4 independently of one another are hydrogen atom, halogen, cyano, nitro, amino, —O—(C1-C7)-alkyl, wherein alkyl is unsubstituted or substituted by phenyl,
        —CF2—CF3, —CF3, —N(R18)2,
        
            wherein R18 is independently of one another chosen from hydrogen atom, —(C1-C7)-alkyl, phenyl, —C(O)-phenyl, —C(O)-pyridyl, —C(O)—NH-phenyl, —C(O)—O-phenyl, —C(O)—O—(C1-C4)-alkyl or —C(O)—(C1-C7)-alkyl, wherein each alkyl, pyridyl or phenyl are unsubstituted or mono- to tri-substituted independently of one another as defined under 1.7.1 to 1.7.11, or R18 together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,
        
        
        S(O)y—R14,
        
            wherein y is zero, 1 or 2, and R14 is —(C1-C10)-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, amino or —N(R18)2,
            wherein R18 is as defined above,
            wherein alkyl is unsubstituted or mono- to tri-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or
        
        
        —C(O)—O—R12, wherein R12 is as defined above,
    
    
    R3 is cyano, nitro, amino, —O—(C1-C7)-alkyl, wherein alkyl is substituted by phenyl, —CF2—CF3, —CF3, —N(R18)2,
    
        wherein R18 is independently of one another chosen from hydrogen, atom,
        —(C1-C7)-alkyl, phenyl, —C(O)-phenyl, —C(O)-pyridyl, —C(O)—NH-phenyl, —C(O)—O-phenyl, —C(O)—O—(C1-C4)-alkyl or —C(O)—(C1-C7)-alkyl, wherein each alkyl, pyridyl or phenyl are unsubstituted or mono- to tri-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or R18 together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,
    
    
     S(O)y—R14,
    
        wherein y is zero, 1 or 2, and R14 is —(C1-C10)-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, amino or —N(R18)2,
        wherein R18 is as defined above,
        wherein alkyl is unsubstituted or mono- to tri-substituted independently of one another as defined under 1.7.1 to 1.7.11, or
    
    
     —C(O)—O—R12, wherein R12 is as defined above,
    R6, R7 and R8 independently of one another are chosen from hydrogen atom or methyl, and
    R5 is as defined above.


Further examples include compounds of formula (II)




and/or a stereoisomeric form of the compound of the formula II and/or a physiologically tolerable salt of the compound of the formula II, wherein;

    R1 and R2 are independently of one another chosen from hydrogen atom, halogen, cyano, amino, —O—(C1-C4)-alkyl, nitro, —CF3, —CF2—CF3, —S(O)y—R14,
    
        wherein y is 1 or 2, R14 is amino, —(C1-C7)-alkyl or phenyl, which phenyl is unsubstituted or mono- to tri-substituted as defined for substituents under 1.7.1 to 1.7.11 above,
        —N(R18)2, wherein R18 is independently of one another chosen from hydrogen atom, —(C1-C7)-alkyl-C(O)—(C1-C7)-alkyl, —C(O)-phenyl, C(O)-pyridyl, —C(O)—NH—(C1-C4)-alkyl, —C(O)—O-phenyl, —C(O)—O—(C1-C4)-alkyl or —(C1-C10)-alkyl, wherein pyridyl, alkyl or phenyl are unsubstituted or mono- to tri-substituted independently of one another as defined under 1.7.1 to 1.7.11, or
        
            R18 together with nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,
        
        
    
    
    R3 is cyano, amino, —O—(C1-C4)-alkyl, nitro, —CF3, —CF2—CF3, —S(O)y—R14, wherein y is 1 or 2, R14 is amino, —(C1-C7)-alkyl or phenyl, which phenyl is unsubstituted or mono- to tri-substituted as defined for substituents under 1.7.1 to 1.7.11 above,
    
        —N(R18)2, wherein R18 is independently of one another chosen from hydrogen atom,
        —(C1-C7)-alkyl-C(O)—(C1-C7)-alkyl, —C(O)-phenyl, —C(O)-pyridyl, —C(O)—O-phenyl, —C(O)—NH—(C1-C4)-alkyl, —C(O)—O—(C1-C4)-alkyl or —(C1-C10)-alkyl, wherein pyridyl, alkyl or phenyl are unsubstituted or mono- to tri-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or
        R18 together with nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms, and
    
    
    R5 is hydrogen atom, —(C1-C10)-alkyl,
    
        wherein alkyl is unsubstituted or mono- to tri-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.4,
        —C(O)—R9 or —S(O)2—R9, wherein
        
            R9 is —(C1-C10)-alkyl, —O—(C1-C10)-alkyl,
            wherein alkyl is unsubstituted or mono- to tri-substituted independently of one another as defined under 1.7.1 to 1.7.4, or phenyl, which is unsubstituted or mono- to tri-substituted as defined under 1.7.1 to 1.7.11, or —N(R18)2, wherein R18 is as defined above.
        
        
    
    


Still further examples are compounds of formula (II), wherein

    R1 is bromo, —CF3 or chloro,
    R2 is hydrogen atom or O—(C1-C2)-alkyl,
    R3 is —N(R18)2, wherein R18 is independently of one another chosen from hydrogen atom, —N—C(O)-pyridyl, —C(O)-phenyl, —(C1-C7)-alkyl, —C(O)—(C1-C4)-alkyl or —C(O)—O—(C1-C4)-alkyl, wherein alkyl or phenyl are unsubstituted or mono- to tri-substituted by substituents independently chosen from halogen or —O—(C1-C2)-alkyl, and
    R5 is hydrogen atom, methyl or —(O)2—CH3.


Specific compounds and all pharmaceutically acceptable salts thereof which are illustrative of the compounds of the invention include the following;




Further specific examples include the following compounds:
N-(6-Chloro-9H-β-carbolin-8-yl)-nicotinamide, as well as the bismesylate salt, bistrifluoracetate salt and bishydrochloride salt of N-(6-Chloro-9H-β-carbolin-8-yl)-nicotinamide, N-(6-Chloro-9H-β-carbolin-8-yl)-3,4-difluoro-benzamide, as well as the hydrochloride salt of N-(6-Chloro-9H-β-carbolin-8-yl)-3,4-difluoro-benzamide, N-(6-Chloro-7-methoxy-9H-β-carbolin-8-yl)-nicotinamide as well as the bistrifluoracetate salt and bishydrochloride salt of N-(6-Chloro-7-methoxy-9H-β-carbolin-8-yl)-nicotinamide and 6-Chloro-N-(6-chloro-9H-β-carbolin-8-yl)-nicotinamide.
The term “alkyl” by itself or as part on another substituent, unless otherwise stated means a straight or branched chain hydrocarbon radical having 1 to 10 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tertiary-butyl, pentyl, hexyl, heptyl, nonyl, octyl, decanyl or cycloalkyl having 3 to 7 carbon atoms such as cylopropyl, cyclobutyl, cyclohexyl or cycloheptyl.
The term “alkoxy” by itself or as part on another substituent, unless otherwise stated means —O-alkyl or —O-substituted alkyl.
The term “heterocycle having 5 to 7 ring atoms” represents a radical of a monocyclic saturated system having 5 to 7 ring members, which contains 1, 2 or 3 heteroatoms as ring members. Examples of heteroatoms are N, O and S. Examples of the term heterocycle having 5 to 7 ring atoms are pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine.
The term “aryl” by itself or as part on another substituent, unless otherwise stated refers to an organic radical derived from an aromatic molecule by removal of one atom; such as phenyl, pyridyl, thiazoly, morpholinyl and naphthyl.
The term “substituted alkyl” means an alkyl radical substituted at one or more positions by one or more radicals of the group halogen, nitro, sulfo, amino, substituted amino, carboxyl, alkoxy, —O-aryl, —O-substituted aryl, and hydroxyl.
The term “substituted aryl” means an aryl radical substituted at one or more positions by one or more radicals of the group halogen, alkyl, substituted alkyl, nitro, sulfo, amino, alkoxy, aryl, substituted aryl, or hydroxyl groups, such as an aryl radical substituted at 1 to 3 positions by 1 to 3 groups.
The term “substituted amino” refers to —N(R13)2 wherein R13 is independently of one another chosen from hydrogen atom, sulfo, alkyl, aryl, —C(O)-alkyl, C(O)—NH-aryl, —C(O)—O-aryl, —C(O)—O-alkyl, or C(O)—O-aryl, wherein each alkyl or aryl may be independently substituted.
The term “sulfo” refers to —S(O)y—R14, wherein R14 is an alkyl, aryl, substituted aryl, substituted alkyl, amino, or substituted amino and y is zero, one or two.
The term “halogen” is understood as meaning fluorine, chlorine, bromine or iodine.
The term “—(C1-C4)-alkyl” is understood as meaning hydrocarbon radicals whose carbon chain is linear or branched and contains 1 to 4 carbon atoms.
The invention further relates to a process for the preparation of the compounds of formula I and/or stereoisomeric forms of the compounds of the formula I and/or physiologically tolerable salts of the compounds of formula I, which comprises

    a) reacting a compound of formula III






    
    
        in which R1, R2, R3, R4, B6, B7, B8 and B9 are each as defined in formula I, with a compound of the formula IV,
    
    






    
    
        in the presence of a acid, to yield a compound of the formula V
    
    






    which is reacted with hydrazine hydrate and later with formaldehyde (R6 is H) or R6CHO to give a compound of formula VI






    
    
        and oxidized to give a compound of formulas VII,
    
    






    
    
        where R1 to R4, R6 to R8 and B6 to B9 are as defined in formula I, a compound of formula (I), or
    
    
    b) a compound of the formula VII is reacted with a compound of the formula VIII

Y—R5  (VIII)
    
        where Y is halogen or —OH and R5 is as defined in formula I, to give a compound of the formula I, or
    
    
    c) resolving a compound of the formula I, which on account of its chemical structure occurs in enantiomeric forms, prepared by process a) or b) into the pure enantiomers by salt formation with enantiomerically pure acids or bases, chromatography on chiral stationary phases or derivatization by means of chiral enantiomerically pure compounds such as amino acids, separation of the diastereomers thus obtained, and removal of the chiral auxiliary groups, or
    d) isolating the compound of the formula I prepared by process a), b) or c) either in free form or, in the case of the presence of acidic or basic groups, converting it into physiologically tolerable salts.


The preparation of physiologically tolerable salts of compounds of the formula I capable of salt formation, including their stereoisomeric forms, is carried out in a manner known per se. With basic reagents such as hydroxides, carbonates, hydrogencarbonates, alkoxides and also ammonia or organic bases, for example trimethyl- or triethylamine, ethanolamine or triethanolamine or alternatively basic amino acids, for example lysine, ornithine or arginine, the carboxylic acids form stable alkali metal, alkaline earth metal or optionally substituted ammonium salts. If the compounds of the formula I contain basic groups, stable acid addition salts can also be prepared using strong acids. For this, both inorganic and organic acids such as hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, benzenesulfonic, p-toluenesulfonic, 4-bromobenzenesulfonic, cyclohexylamidosulfonic, trifluoromethylsulfonic, acetic, oxalic, tartaric, succinic or trifluoroacetic acid are suitable.
The invention also relates to pharmaceuticals which comprise an efficacious amount of at least one compound of the formula I and/or of a physiologically tolerable salt of the compounds of the formula I and/or an optionally stereoisomeric form of the compounds of the formula I, together with a pharmaceutically suitable and physiologically tolerable excipient, additive and/or other active compounds and auxiliaries.
On account of the pharmacological properties, the compounds according to the invention are suitable for the prophylaxis and therapy of all those disorders in whose course an increased activity of IkB kinase is involved. These include, for example, asthma, rheumatoid arthritis (in the case of inflammation), osteoarthritis, Alzheimer's disease, carcinomatous disorders (potentiation of cytotoxic therapies), cardiac infarct or atherosclerosis.
The pharmaceuticals according to the invention are in general administered orally or parentally or by rectal, inhale or transdermal administration.
The invention also relates to the use of the compounds of the formula I




and/or a stereoisomeric form of the compounds of the formula I and/or a physiologically tolerable salt of the compounds of the formula I,

for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of IkB kinase is involved,

wherein B6, B7, B8 and B9 are independently selected from the group consisting of carbon atom and nitrogen atom and wherein B6, B7, B8 and B9 together are no more than two nitrogen atoms at the same time;

where the substituents R1, R2, R3, R4 and R8 may be independently chosen from

    
    
        1. hydrogen atom,
        2. halogen,
        3. —OH,
        4. —CN,
        5. sulfo,
        6. —NO2,
        7. —NH2,
        8. alkoxy,
        9. substituted amino,
        10. —NH—C(O)—R15, wherein R15 is a heterocycle having 5 to 7 ring atoms, an alkyl, an aryl, a substituted aryl or a substituted alkyl,
        11. —COOH,
        12. —O—R10, wherein R10 is alkyl, substituted alkyl or aryl,
        13. —C(O)—R12, wherein R12 is alkyl, substituted alkyl or aryl,
        14. —C(O)—O—R12, wherein R12 is as defined in 13, above,
        15. aryl,
        16. —O-aryl,
        17. substituted aryl,
        18. —O-substituted aryl,
        19. alkyl,
        20. substituted alkyl,
        21. —CF3 or
        22. —CF2—CF3,

provided that at least one of R1, R2, R3, R4 and R8 is not a hydrogen atom,

    
    
    R5 is 1. hydrogen atom,
    
        2. alkyl,
        3. alkyl radical, substituted at one or more positions by one or more of the radicals, halogen, amino or hydroxyl,
        4. —C(O)—R9 or
        5. —S(O)2—R9, in which
        
            R9 is a) alkyl,
            
                b) alkyl radical, substituted at one or more positions by one or more of the radicals, halogen, amino or hydroxyl,
                c) aryl,
                d) aryl radical, substituted at one or more positions by one or more of the radicals, halogen, amino, or hydroxyl,
                e) —NH2,
                f) alkoxy or
                g) substituted amino, and
            
            
        
        
    
    
    R6 and R7 may be independently chosen from
    
        1. hydrogen atom,
        2. halogen,
        3. —OH,
        4. methyl,
        5. —O—(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to tri-substituted by substituents independently chosen from
        
            5.1 aryl,
            5.2 halogen,
            5.3 —NO2,
            5.4 sulfo,
            5.5 —COOH,
            5.6 —NH2,
            5.7 —O—(C1-C4)-alkyl or
            5.8 —OH, or
        
        
        6. —N(R13)2, wherein R13 is independently of one another chosen from hydrogen atom, aryl, —C(O)—(C1-C4)-alkyl or substituted aryl or alkyl, wherein said —C(O)—(C1-C4)-alkyl is unsubstituted or mono- to tri-substituted independently of one another as defined under 5.1 to 5.8, or
        
            R13 together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms.
        
        
    
    


Following are examples of the use of the compounds of formula I, wherein

    B6, B7, B8, and B9 are each a carbon atom,
    R1, R2, R3, R4 and R8 are independently chosen from
    
        1. hydrogen atom,
        2. halogen,
        3. —CN,
        4. —COOH,
        5. —NO2,
        6. —NH2,
        7. —O—(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from
        
            7.1 phenyl, which is unsubstituted or mono- to penta-substituted by substituents independently chosen from halogen or —O—(C1-C4)-alkyl,
            7.2 halogen,
            7.3 —NH2,
            7.4 —OH,
            7.5 —COOR16, wherein R16 is hydrogen atom or —(C1-C10)-alkyl,
            7.6 —NO2,
            7.7 —S(O)y—R14, wherein y is zero, 1 or 2, R14 is —(C1-C10)-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11, amino or —N(R3)2,
            
                wherein R13 is independently of one another chosen from hydrogen atom, phenyl, —(C1-C10)-alkyl, —C(O)—(C1-C7)-alkyl, —C(O)-phenyl, —C(O)—NH—(C1-C7)-alkyl, —C(O)—O-phenyl, —C(O)—NH-phenyl, —C(O)—O—(C1-C7)-alkyl, —S(O)y—R14 wherein R14 and y are as defined above,
                and wherein R13 alkyl or phenyl groups in each case are unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above, or
                R13 together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,
            
            
            7.8 —O-phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above,
            7.9 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,
            7.10 —(C3-C7)-cycloalkyl or
            7.11 ═O,
        
        
        8. —N(R13)2, wherein R13 is as defined in 7.7 above,
        9. —NH—C(O)—R15 wherein R15 is
        
            9.1 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,
            
                wherein said radical is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above, —CF3, benzyl or by —(C1-C10)-alkyl, wherein alkyl is mono to tri-substituted independently of one another as defined under 7.1 to 7.11 above,
            
            
            9.2 —(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above or by —O—(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above,
            9.3 —(C3-C7)-cycloalkyl,
            9.4 —N(R13)2, wherein R13 is as defined in 7.7 above, or
            9.5 phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above, by —O—(C1-C10)-alkyl, by —CN, by —CF3, by —(C1-C10)-alkyl, wherein alkyl is mono to tri-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above, or by two substituents of the phenyl radical which form a dioxolan ring,
        
        
        10. —S(O)y—R14, wherein R14 and y are as defined in 7.7 above,
        11. —C(O)—R12, wherein R12 is phenyl or —(C1-C7)-alkyl, wherein phenyl or alkyl are unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above,
        12. —C(O)—O—R12, wherein R12 is as defined in 11, above,
        13. —(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above,
        14. —O—(C1-C6)-alkyl-O—(C1-C6)-alkyl,
        15. —O—(C0-C4)-alkyl-(C3-C7)-cycloalkyl,
        16. —(C1-C4)-alkyl-N(R13)2, wherein R13 is as defined in 7.7 above
        17. —CF3 or
        18. —CF2—CF3,

provided that at least one of R1, R2, R3, R4 and R8 is not a hydrogen atom,

    
    
    R5 is 1. hydrogen atom,
    
        2. —(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.4 above,
        3. —C(O)—R9, wherein R9 is
        
            —NH2, —(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.4, or —N(R13)2, wherein R13 is as defined in 7.7 above, or
        
        
        4. —S(O)2—R9, wherein R9 is as defined in 3 above,
    
    
    or R4 and R5 together with the atom to which they are bonded form a heterocycle,
    or R3 and R5 together with the atom to which they are bonded form a heterocycle containing an additional oxygen atom in the ring and
    R6 and R7 independently of one another are chosen from hydrogen atom or methyl.


Further examples include the use of compounds of formula I for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of IkB kinase is involved, wherein

    B6, B7, B8, and B9 are each a carbon atom,
    R1, R2, R3 and R4 independently of one another are hydrogen atom, halogen, cyano, nitro, amino, —O—(C1-C7)-alkyl, phenyl, —O-phenyl, —CF2—CF3, —CF3, N(R13)2,
    
        wherein R13 is independently of one another chosen from hydrogen atom, —(C1-C7)-alkyl, phenyl, —C(O)-phenyl, —C(O)-pyridyl, —C(O)—NH-phenyl, —C(O)—O-phenyl, —C(O)—O—(C1-C4)-alkyl, —C(O)—(C1-C7)-alkyl or —(C1-C10)-alkyl, wherein alkyl, pyridyl or phenyl are unsubstituted or mono- to tri-substituted by substituents independently chosen from those as defined under 7.1 to 7.11, or R13 together with nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,
    
    
     —S(O)y—R14,
    
        wherein y is zero, 1 or 2, and R14 is —(C1-C10)-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta-substituted as defined for substituents under 7.1 to 7.11, amino or —N(R13)2,
        wherein R13 is as defined above,
        wherein alkyl is unsubstituted or mono- to tri-substituted independently of one another as defined under 7.1 to 7.11, or
    
    
     —C(O)—O—R12, wherein R12 is as defined as in 11, above,
    R6, R7 and R8 independently of one another are hydrogen atom, methyl, amino, —N(R13)2, wherein R13 is as defined above,

provided that at least one of R1, R2, R3, R4 and R8 is not a hydrogen atom, and R5 is as defined immediately above.



Moreover, examples include the use of compounds of formula II




and/or a stereoisomeric form of the compounds of the formula II and/or a physiologically tolerable salt of the compounds of the formula II,

for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of IkB kinase is involved, wherein;

    R1, R2 and R3 are independently chosen from hydrogen atom, halogen, cyano, amino, —O—(C1-C4)-alkyl, nitro, —CF3, —CF2—CF3, —S(O)y—R14, wherein y is 1 or 2,
    
        R14 is amino, —(C1-C7)-alkyl, phenyl, which is unsubstituted or mono- to tri-substituted by substituents independently chosen from those as defined under 7.1 to 7.9, or —N(R13)2, wherein
        R13 is independently of one another chosen from —C(O)-pyridyl, hydrogen atom, —(C1-C7)-alkyl-C(O)—(C1-C7)-alkyl, —C(O)-phenyl, —(C1-C10)-alkyl, —C(O)—NH—(C1-C4)-alkyl, —C(O)—O-phenyl or —C(O)—O—(C1-C4)-alkyl, wherein
        
            pyridyl, alkyl or phenyl are unsubstituted or mono- to tri-substituted independently of one another as defined under 7.1 to 7.11, or
            R13 together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

provided that at least one of R1, R2 and R3 is not a hydrogen atom, and

        
        
    
    
    R5 is hydrogen atom, —(C1-C10)-alkyl,
    
        wherein alkyl is unsubstituted or mono- to tri-substituted by substituents independently chosen from those as defined under 7.1 to 7.4,
        —C(O)—R9 or —S(O)2—R9, wherein
        
            R9 is —(C1-C10)-alkyl, —O—(C1-C10)-alkyl,
            wherein alkyl is unsubstituted or mono- to tri-substituted by substituents independently chosen from those as defined under 7.1 to 7.4,
            phenyl, which is unsubstituted or mono- to tri-substituted by substituents independently chosen from those as defined under 7.1 to 7.11, or —N(R13)2,
            wherein R13 is as defined directly above.
        
        
    
    


Still further examples include the use of the compounds of formula II for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of IkB kinase is involved, wherein

    R1, R2 and R3 are independently chosen from hydrogen atom, halogen, cyano, amino, —O—(C1-C4)-alkyl, nitro, —CF3 or N(R13)2,
    
        wherein R13 is independently of one another chosen from hydrogen atom, —(C1-C7)-alkyl, —C(O)—(C1-C7)-alkyl, —C(O)-pyridyl, —C(O)-phenyl or —C(O)—O—(C0-C4)-alkyl, wherein alkyl or phenyl are unsubstituted or mono- to tri-substituted by substituents independently chosen from halogen or —O—(C1-C4)-alkyl, and
    
    
    R5 is hydrogen atom, —C(O)—CH3, methyl, —S(O)2—CH3, —C(O)-morpholinyl, —CH2—CH2—OH or —CH2—C(O)—NH2,

provided that no more than two of R1, R2, R3 and R5 are a hydrogen atom.



Further examples include the use of the compounds of formula II for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of IkB kinase is involved, wherein

    R1 is bromo, —CF3 or chloro, R2 is hydrogen atom or O—(C1-C2)-alkyl,
    R3 is hydrogen atom, bromo, chloro or —N(R13)2,

wherein R13 is independently of one another chosen from hydrogen atom, —C(O)-phenyl, —(C1-C7)-alkyl, —C(O)—(C1-C4)-alkyl or —C(O)—O—(C1-C4)-alkyl, wherein alkyl or phenyl are unsubstituted or mono- to tri-substituted by substituents independently chosen from halogen or —O—(C1-C2)-alkyl, and

    R5 is hydrogen atom, —C(O)—CH3, methyl or —S(O)2—CH3,

provided that no more than two of R1, R2, R3 and R5 are a hydrogen atom.



Specific examples include the use of the compounds of formula II for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of IkB kinase is involved, wherein

    R1 is chloro, R2 and R3 are each hydrogen atom, and R5 is —C(O)—CH3, or
    R1 is bromo, R2 and R3 are each hydrogen atom, and R5 is —C(O)—CH3, or
    R1 is chloro, R3 is —N—C(O)—CH2—O—CH3 and R2 and R5 are each hydrogen atom, or
    R1 is chloro, R3 is —N—C(O)-para-fluoro-phenyl and R2 and R5 are each hydrogen atom, or R1 and R3 are each chloro, R2 is —C(O)—CH3 and R5 is hydrogen atom, or
    R1 and R3 are each chloro, R5 is hydrogen atom and R2 is —C(O)—CH2—CH3.


On account of the pharmacological properties, the compounds according to the invention are suitable for the prophylaxis and therapy of all those disorders in whose course an increased activity of IkB kinase is involved. Disorders in whose course an increased activity of IkB kinase is involved include, for example the treatment of joint inflammation, including arthritis, rheumatoid arthritis and other arthritic conditions such as rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis and osteoarthritis. Additionally, the compounds are useful in the treatment of acute synovitis, tuberculosis, atherosclerosis, muscle degeneration, cachexia, Reiter's syndrome, endotoxaemia, sepsis, septic shock, endotoxic shock, gram negative sepsis, gout, toxic shock syndrome, chronic pulmonary inflammatory diseases including asthma and adult respiratory distress syndrome, silicosis, pulmonary sarcoidosis, bone resorption diseases, reperfusion injury, carcinoses, leukemia, sarcomas, lymph node tumors, skin carcinoses, lymphoma, apoptosis, graft versus host reaction, allograft rejection and leprosy. Furthermore, the compounds are useful in the treatment of: infections such as viral infections, for example HIV, cytomegalovirus (CMV), influenza, adenovirus and the Herpes group of viruses, parasitic infections, for example malaria such as cerebral malaria, and yeast and fungal infections, for example fungal meningitis; fever and myalgias due to infection; AIDS; AIDS related complex (ARC); cachexia secondary to infection or malignancy; cachexia secondary to acquired immune deficiency syndrome (AIDS) or to cancer; keloid and scar tissue formation; pyresis; diabetes; and inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The compounds of the invention are also useful in the treatment of diseases of or injury to the brain in which over-expression of TNFα has been implicated such as multiple sclerosis, and head trauma. The compounds according to the invention are also useful in the treatment of psoriasis, Alzheimer's disease, carcinomatous disorders (potentiation of cytotoxic therapies), cardiac infarct, chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS).
The invention also relates to a process for the production of a pharmaceutical, which comprises bringing at least one compound of the formula I into a suitable administration form using a pharmaceutically suitable and physiologically tolerable excipient and, if appropriate, further suitable active compounds, additives or auxiliaries.
Suitable solid or pharmaceutical preparation forms are, for example, granules, powders, coated tablets, tablets, (micro)capsules, suppositories, syrups, juices, suspensions, emulsions, drops or injectable solutions, and preparations having protracted release of active compound, in whose preparation customary auxiliaries, such as excipients, disintegrants, binders, coating agents, swelling agents, glidants or lubricants, flavourings, sweeteners and solubilizers are used. Frequently used auxiliaries which may be mentioned are magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, lactoprotein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils such as cod liver oil, sunflower, groundnut or sesame oil, polyethylene glycol and solvents such as, for example, sterile water and mono- or polyhydric alcohols such as glycerol.
The pharmaceutical preparations may be produced and administered in dose units, each unit containing as active constituent a certain dose of the compound of the formula I according to the invention. In the case of solid dose units such as tablets, capsules, coated tablets or suppositories, this dose can be up to approximately 1000 mg, such as from approximately 50 mg to 300 mg and in the case of injection solutions in ampoule form up to approximately 300 mg, such as from approximately 10 mg to 100 mg.
For the treatment of an adult patient weighing approximately 70 kg, depending on the efficacy of the compound according to formula I, daily doses of approximately 20 mg to 1000 mg of active compound, such as from approximately 100 mg to 500 mg, are indicated. Under certain circumstances, however, even higher or lower daily doses may be appropriate. The administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or else of a number of smaller dose units and by multiple administration of subdivided doses at specific intervals.
As a rule, final products are determined by mass-spectroscopic methods (FAB-, ESI-MS). Temperatures are given in degrees Celsius, RT means room temperature (22° C. to 26° C.). Abbreviations used are either explained or correspond to the customary conventions.
The following examples are numbered so as to correspond to the compounds of Table 1, below.


EXAMPLE 1
7-bromo-β-carboline
A solution of norharmane (600 mg, 3.57 mmol) in tetrahydrofuran (THF; 50 ml) was treated with bromine (0.40 ml, 7.80 mmol) at RT while stirring. After stirring for 18 h at RT, the reaction was concentrated under reduced pressure and the resulting residue was sonicated in 10% aqueous Na2CO3 (100 ml). The product was filtered and washed with water to give 905 mg of crude product. The crude product was crystallized from xylenes to provide in two crops 580 mg of 7-bromo-β-carboline.
EXAMPLE 2
1-acetyl-7-bromo-β-carboline
A solution of Example 1 (25 mg, 0.1 mmol) in dimetylformamide (DMF; 2 ml) was treated with 0.10 ml of 1M aqueous NaOH (0.10 mmol). After stirring at RT for 30 minutes, acetic anhydride (0.010 ml, 0.095 mmol) was added and reaction stirred 18 h at RT. The reaction was partitioned in EtOAc and 5% citric acid and the organic layer washed with water, dried (brine; MgSO4), and concentrated to give 23 mg of crude product. The crude product was chromatographed (7:3 hexane-acetone) on silica gel to give 10 mg of 1-acetyl-7-bromo-β-carboline.
EXAMPLE 3
7-fluoro-β-carboline
A mixture of 5-fluorotryptamine hydrochloride (200 mg, 0.93 mmol) in EtOAc (4 ml) and water (2 ml) was treated with glyoxalic acid hydrate (90 mg, 0.98 mmol). The pH of the aqueous layer was adjusted to 5 (with 5% NaHCO3 then 1M HCl) and the mixture stirred vigorously at RT for 18 h. The mixture was then diluted with hexane (4 ml) and the product filtered and washed with water and (1:1) hexane-ethyl acetate.
The crude product from above in 6N HCl (3 ml) was treated 3 times with concentrated HCl (0.050 ml) every 15 min while refluxing. After refluxing for a total of 45 min, the reaction was concentrated to give a residue. The above residue was slurred in xylenes with triethylamine (0.40 ml, 2.9 mmol) and 10% Pd/C (200 mg). The mixture was refluxed for 1 h and then filtered hot through celite. The filtrate was concentrated and the residue chromatographed (5:95 methanol-chloroform) on silica gel to give 25 mg of 7-fluoro-β-carboline.
EXAMPLE 4
7-isopropyl-β-carboline hydrochloride
A mixture of 4-isopropylphenylhydrazine hydrochloride (660 mg, 3.55 mmol) and 4-phthalimidobutanal diethyl acetal (1.15 g, 3.95 mmol) in Ethanol (EtOH; 30 ml) was heated at 60° C. to 65° C. for 1 h with water (0.050 ml). The mixture was then treated with concentrated HCl (0.50 ml) and refluxed for 14 h. After concentrating the reaction, the residue was portioned in methylene chloride and saturated aqueous NaHCO3. The aqueous solution was extracted with methylene chloride (3 times) and the combined organic solutions were dried (MgSO4) and concentrated to give after chromatography (4:1 hexane-ethyl acetate) on silica gel 146 mg of product.
The above product was treated with hydrazine hydrate (1 ml) in EtOH (4 ml) and water (1 ml) and stirred at RT overnight. After concentrating the reaction to an aqueous mixture, the product was extracted with methylene chloride (3 times). The combined organic solution was dried (MgSO4) and concentrated. The residue was redissolved in methylene chloride and treated with 1M HCl in ether. The precipitate was collected and washed with ether and hexane and dried to provide 102 mg of 6-isopropyltryptamine hydrochloride salt. This tryptamine obtained above was transformed into 7-Isopropyl-β-carboline according to the procedure used in example 3. The hydrochloride salt was obtained by treating a solution of 7-Isopropyl-β-carboline in methylene chloride with 1M HCl in ether and concentrating. The residue was triturated with (1:1) methylene chloride-hexane to give 15 mg of 7-isopropyl-β-carboline hydrochloride.
EXAMPLE 5
7-cyano-β-carboline
A dark solution of example 1 (190 mg, 0.62 mmol) and CuCN (110 mg, 1.22 mmol) in N-methyl 2-pyrrolidone (1.5 ml) was heated in a sealed reaction tube at 200° C. for 48 h. The mixture was filtered and the filtrate was diluted with water (50 ml). A brown solid that precipitated was filtered, washed with water, saturated aqueous NaHCO3, and then methanol. This material was dissolved in DMSO and diluted with aqueous HCl. This homogeneous dark solution was decolorized with charcoal, filtered and concentrated to give a concentrated solution in DMSO. This DMSO solution was partitioned in (1:1) EtOAc-THF and saturated aqueous NaHCO3. The organic solution was dried (MgSO4) and concentrate to give 8 mg of 7-cyano-β-carboline.
EXAMPLE 6
7-nitro-β-carboline hydrochloride
Norharmane (100 mg, 0.60 mmol) was treated with concentrated nitric acid (1.0 ml) and the resulting suspension was heated to 65° C. until the mixture became homogeneous (3 to 4 min). The solution was carefully poured into water (20 ml), and the precipitate filtered and washed with water then methanol. The solid was suspended in saturated aqueous NaHCO3 and stirred vigorously before filtering and washing with water. The solid was taken up in hot methanol and this solution treated with 1M HCl in ether (5 ml). The solution was concentrated and the residue triturated with ether to provide
58 mg of a 7:3 mixture of 7-nitro-β-carboline hydrochloride and 9-nitro-β-carboline hydrochloride.
EXAMPLE 7
7-carboxy-β-carboline trifluoroacetate
Crude product from example 5 (from 210 mg of example 1, 0.85 mmol) was treated with 6 M HCl in a sealed reaction tube for 15 h at 110° C. The reaction was evaporated to give a concentrated solution of product in N-methyl 2-pyrrolidone. A portion (half) was purified by preparative HPLC using a C18-packed column and eluting with a gradient (5:95 to 50:50) of water-acetonitril (with 0.1% trifluoracetic acid). The pure fractions were combined and lyophilized to provide 11 mg of 7-carboxy-β-carboline trifluoroacetate.
EXAMPLE 8
7,9-dibromo-β-carboline hydrochloride
A solution of the product from example 1 (140 mg, 0.58 mmol) in THF (2 ml) was treated with bromine (0.50 ml). After 10 min at RT, the reaction was diluted with chloroform and the product was filtered. The filtered product was taken up in methanol and treated with 1M HCl in ether and concentrated. The residue was triturated with ether to provide 160 mg of 7,9-dibromo-β-carboline hydrochloride.
EXAMPLE 9
7,9-dichloro-β-carboline
To a suspension of norharmane (84 mg, 0.50 mmol) in water (3 ml) at RT was added 1M aqueous HCl (1.1 ml, 1.1 mmol). To this homogenous solution was added N-chlorosuccinimide (747 mg, 5.58 mmol) portionwise and the resulting solution was stirred at 60° C. to 70° C. for 3 h. The reaction was partitioned in EtOAc and saturated aqueous NaHCO3 and the organic layer was dried (brine; MgSO4) and then concentrated. The residue was chromatographed (2:3 THF-hexane) on silica gel to give 24 mg of 7,9-dichloro-β-carboline after triturating with (1:1) methylene chloride-hexane, then with hexane.
EXAMPLE 10
1-acetyl-7-bromo-β-carboline
To a suspension of NaH (95%, 14 mg, 0.60 mmol) in DMF (1.0 ml) at 5° C. to 10° C. was added the product from example 1 (74 mg, 0.30 mmol). The resulting mixture was stirred for 15 min at 5° C. to 10° C. before adding methanesulfonylchloride (0.030 ml, 0.38 mmol). The reaction was allowed to warm to RT and stirred for 2 h before partitioning into saturated aqueous NaHCO3 and EtOAc. After stirring the mixture overnight, the organic layer was washed with water, dried (brine; MgSO4), and concentrated. The residue was purified by chromatography (1:1 hexane-ethyl acetate) on silica gel to give 23 mg of 1-acetyl-7-bromo-β-carboline.
EXAMPLE 11
7-bromo-1-methyl-β-carboline
To a suspension of NaH (95%, 6 mg, 0.24 mmol) in DMF (2.0 ml) at 5° C. to 10° C. was added the product from example 1 (50 mg, 0.20 mmol). The resulting mixture was stirred for 15 min at 5° C. to 10° C. before adding methyl-iodide (0.030 ml, 0.20 mmol) at 0° C. to 5° C. The reaction was stirred for 12 h at 0° C. to 5° C. before partitioning into water and EtOAc. The organic layer was washed with water, dried (brine; MgSO4), and concentrated. The residue was purified by chromatography (gradient, 1:3 hexane-ethyl acetate to ethyl acetate) on silica gel to give 10 mg of 7-bromo-1-metyhl-β-carboline.
EXAMPLE 12
7-chloro-β-carboline
To a solution of norharmane (2.0 g, 11.9 mmol) in water (89 ml) and 1M aqueous HCl (29.8 ml, 29.8 mmol) was added N-chlorosuccinimide (3.17 g, 23.8 mmol) portionwise. The resulting solution was stirred at RT for 6 h, and then at 0° C. to 5° C. for 12 h. The reaction was diluted with water (100 ml) and basified cautiously with solid K2CO3 (4.3 g). After stirring at RT for 1 h, the product was collected and washed with water. The crude product was refluxed in chloroform for 1 h and filtered after cooling to 15° C. to provide 2.05 g of 7-chloro-β-carboline.
EXAMPLE 13
1-acetyl-7-chloro-β-carboline
To a solution of the product from example 12 (104 mg, 0.50 mmol) in DMF (2.0 ml) at 3° C. to 5° C. was added NaH (95%, 15 mg, 0.625 mmol). The resulting mixture was stirred for 15 min before adding acetic anhydride (0.083 ml, 0.875 mmol). The reaction was allowed to warm to RT and stirred for 3 h before pouring into with water (25 ml). The slurry was stirred for 12 h, and the product collected to give after chromatography (1:3 hexane-ethyl acetate) on silica gel 82 mg of 1-acetyl-7-chloro-β-carboline.
EXAMPLE 14
7-chloro-9-nitro-β-carboline
A mixture of the product from example 12 (500 mg, 2.48 mmol) in concentrated nitric acid (20 ml) was stirred at RT for 22 h. The reaction mixture was carefully poured into cold (3° C. to 5° C.) water (50 ml), and after stirring for 2 h the precipitate was collected. The solid was suspended in saturated aqueous NaHCO3 (50 ml) and stirred at RT for 12 h. The product was filtered and washed with water to provide 550 mg of 7-chloro-9-nitro-β-carboline
EXAMPLE 15
9-amino-7-chloro-β-carboline
To a suspension of the product from example 14 (548 mg, 2.22 mmol) in EtOH (14 ml) at 65° C. to 70° C. was added tin chloride dihydrate (2.5 g, 11.1 mmol). Thereafter, 6M aqueous HCl (14 ml) was added dropwise. The mixture was stirred at 70° C. to 80° C. for 3.5 h and then partitioned slowly into saturated aqueous NaHCO3 (150 ml) and EtOAc (100 ml). The aqueous phase was extracted (2 times) and the combined organic solutions dried (brine; NaSO4) and concentrated to give 484 mg of 9-amino-7-chloro-β-carboline.
EXAMPLE 16
9-amino-7-chloro-β-carboline trifuoroacetate
To a solution of the product from example 15 (35 mg, 0.16 mmol) in pyridine (0.80 ml) was added acetic anhydride (0.018 ml, 0.19 mmol). The resulting mixture was allowed to stand at RT for 12 h before pouring into water (15 ml). The crude product was filtered and purified by preparative HPLC using a C18-packed column and eluting with a gradient (5:95 to 60:40) of water-acetonitril (with 0.1% trifluoracetic acid). The pure fractions were combined and lyophilized to provide 18 mg of 9-amino-7-chloro-β-carboline trifluoroacetate.
EXAMPLE 17
7-bromo-1-carbonyl-(4′-morpholine)-β-carboline
A solution of the product from example 1 (125 mg, 0.51 mmol) in DMF (2 ml) was treated with 0.55 ml of 1M aqueous NaOH (0.55 mmol). After stirring at RT for 30 minutes, 4-morpholinecarbonyl chloride (0.060 ml, 0.51 mmol) was added and reaction stirred 18 h at RT. The reaction was partitioned in EtOAc and 5% citric acid and the organic layer washed with water, dried (brine; MgSO4), and concentrated. The residue was chromatographed (7:3 hexane-acetone) on silica gel to give 105 mg of 7-bromo-1-carbonyl-(4′-morpholino)-β-carboline.
EXAMPLE 18
1-(2′-ethylacetate)-7-chloro-β-carboline
To a suspension of NaH (95%, 28 mg, 1.15 mmol) in DMF (1.0 ml) at 5° C. to 10° C. was added the product from example 12 (202 mg, 1.0 mmol) in DMF (3 ml). The resulting mixture was stirred for 30 min at 5° C. to 10° C. before adding ethyl bromoacetate (0.116 ml, 1.05 mmol). The reaction was allowed to be stirred for 1.5 h and then the reaction was diluted with saturated aqueous NaHCO3 (30 ml). The product was extracted with EtOAc (30 ml; 2 times each 15 ml), and the combined organic extracts were dried (brine; MgSO4) then concentrated. The residue was purified by chromatography (1:3 hexane-ethyl acetate) on silica gel to give 270 mg of 1-(2′-ethylacetate)-7-chloro-β-carboline.
EXAMPLE 19
1-(2′-ethanoyl)-7-chloro-β-carboline
To a solution of the product from example 18 (50 mg, 0.17 mmol) in THF (1.7 ml) at 5° C. to 10° C. was added 1M LAH in THF (0.17 ml, 0.17 mmol). The resulting mixture was stirred for 2 h at 5° C. to 10° C. before adding EtOAc (0.10 ml). The mixture was subsequently diluted with EtOAc (5 ml) and slowly treated with saturated aqueous NaHCO3 (5 ml). After diluting with water (10 ml) and brine (10 ml) the mixture was extracted with EtOAc. The organic solution was dried (brine; MgSO4) then concentrated to give 42 mg of 1-(2′ethanol)-7-chloro-β-carboline.
EXAMPLE 20
1-(2′-acetyl)-7-chloro-β-carboline
To a solution of the product from example 18 (107 mg, 0.37 mmol) in MeOH (3.7 ml) at RT was added water (3.7 ml) followed by treatment with 1M aqueous NaOH (0.41 ml, 0.41 mmol). The resulting mixture was stirred for 2 h and the volatile removed under reduced pressure. The mixture was subsequently diluted with water (5 ml) and the pH adjusted to 5 to 6. The precipitate was filtered and washed with water to give 96 mg of 1-(2′-acetyl)-7-chloro-β-carboline.
EXAMPLE 21
8-methoxy-β-carboline
Prepared from 6-methoxytryptamine using the procedure as in example 3.
EXAMPLE 22
See Table 1 for Structure
To a solution of the product from example 20 (59 mg, 0.23 mmol) in DMF (2.8 ml) at RT was added p-nitrophenol (40 mg, 0.29 mmol) followed by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (48 mg, 0.25 mmol). The resulting mixture was stirred for 1.5 h at RT and then ammonium bicarbonate (55 mg, 0.69 mmol) was added. The reaction was stirred for 18 h at RT and then poured into water (20 ml). The aqueous mixture was basified to pH of about 10 with K2CO3. The precipitate was filtered and washed with water to give 47 mg of the title compound.
EXAMPLE 23
8-hydroxy-2-methyl-β-carboline
A solution of harmine (616 mg, 2.9 mmol) in dichloroethane (20 ml) was treated with 2.0 ml of 1M BBr3 (4 mmol) in dichloroethane. The reaction was stirred at 60° C. for 48 h and then cooled to 0° C. before quenching with MeOH (5 ml). The reaction was concentrated and the residue triturated with methanol to give 413 mg of 8-hydroxy-2-methyl-β-carboline.
EXAMPLE 24
6,8-dibromo-7-methoxy-β-carboline
A solution of the product from example 30 (90 mg, 0.45 mmol) in acetic acid (8 ml) was treated with bromine (0.025 ml, 0.48 mmol). The reaction was stirred at RT for 18 h and then concentrated. The residue was partitioned in EtOAc and aqueous NaHCO3. The organic layer was dried (brine; MgSO4) and concentrated. The residue was purified by chromatography. (5:4 hexane-acetone) on silica gel to give 3 mg of 6,8-dibromo-7-methoxy-β-carboline.
EXAMPLE 25
See Table 1 for Structure
A solution of the product from example 23 (60 mg, 0.30 mmol) in DMF (3 ml) was treated with K2CO3 (100 mg) and t-butyl bromoacetate (0,040 ml, 0.27 mmol). After stirring at RT for 18 h, the reaction was partitioned in EtOAc and water. The organic layer was dried (brine; MgSO4) and then concentrated. The residue was chromatographed (1:1 hexane-EtOAc) on silica gel to give 20 mg of the title compound.
EXAMPLE 26
See Table for Structure
A solution of the product from example 23 (50 mg, 0.25 mmol) in DMF (3 ml) was treated with K2CO3 (100 mg) and benzyl bromide (0,030 ml, 0.25 mmol). After stirring at RT for 18 h, the reaction was partitioned in EtOAc and water. The organic layer was dried (brine; MgSO4) and then concentrated. The residue was chromatographed (1:1 hexane-EtOAc) on silica gel to give 12 mg of the title compound.
EXAMPLE 27
7-ethoxy-2-methyl-β-carboline
A solution of the product from example 23 (60 mg, 0.30 mmol) in DMF (3 ml) was treated with K2CO3 (100 mg) and ethyl iodide (0,029 ml, 0.36 mmol). After stirring at RT for 18 h, the reaction was partitioned in EtOAc and water. The organic layer was dried (brine; MgSO4) and then concentrated. The residue was chromatographed (1:1 hexane-acetone) on silica gel to give 20 mg of 7-ethoxy-2-methyl-β-carboline.
EXAMPLE 28
7-bromo-2-methyl-β-carboline
Prepared from harmane using the same procedure as in example 1.
EXAMPLE 29
See Table 1 for Structure
A solution of the product from example 23 (60 mg, 0.30 mmol) in DMF (3 ml) was treated with K2CO3 (100 mg) and acetic anhydride (0,034 ml, 0.36 mmol). After stirring at RT for 18 h, the reaction was partitioned in EtOAc and water. The organic layer was dried (brine; MgSO4) and then concentrated. The residue was chromatographed (1:1 hexane-acetone) on silica gel to give 18 mg of the title compound.
EXAMPLE 30
7-methoxy-β-carboline
Prepared from 5-methoxytryptamine using the procedure in example 3.
EXAMPLE 31
8-fluoro-β-carboline
Prepared from 6-fluorotryptamine using the same procedure as in example 3.
EXAMPLE 32
7-bromo-2-methyl-8-methoxy-β-carboline
Prepared from harmine using the same procedure as in example 1.
EXAMPLE 33
7-hydroxy-β-carboline
Prepared from the product of example 30 using the procedure in example 23.
EXAMPLE 34
7-chloro-8-fluoro-β-carboline
Prepared from the product of example 31 using the procedure in example 12.
EXAMPLE 35
7-methoxy-1-methyl-β-carboline
Prepared from the product of example 30 using the procedure in example 11.
EXAMPLE 36
9-chloro-8-methoxy-β-carboline trifluoroacetate and EXAMPLE 37 7,9-dichloro-8-methoxy-β-carboline trifluoroacetate
A solution of the product from example 21 (195 mg, 1.0 mmol) in 1M HCl (3 ml) was treated with N-chlorosuccinimide (270 mg, 2 mmol) portionwise and the resulting solution was stirred at 60° C. to 70° C. for 3 h. The reaction was evaporated and the crude product purified by preparative HPLC using a C18-packed column and eluting with a gradient (5:95 to 50:50) of water-acetonitril (with 0.1% trifluoroacetic acid). The pure fractions of each product were combined and lyophilized to provide 78 mg of 9-chloro-8-methoxy-β-carboline trifluoroacetate and 51 mg of 7,9-dichloro-8-methoxy-β-carboline trifluoroacetate.
EXAMPLE 38
7,9-dichloro-8-hydroxy-β-carboline
A mixture of the product of example 37 (590 mg, 2.21 mmol) in methylene chloride (25 ml) at 35° C. was treated with a solution of BBr3 in methylene chloride (1M, 6 ml, 6 mmol). After refluxing for 3 h, the reaction was quenched with methanol (5 ml) and then concentrated. The residue was slurred in 60% NaHCO3 solution, the product filtered and washed with water to give 500 mg of 7,9-dichloro-8-hydroxy-β-carboline.
EXAMPLE 39
7,9-dichloro-8-ethoxy-β-carboline
A mixture of the product of example 38 (35 mg, 0.14 mmol), K2CO3 (100 mg), and ethyl iodide (0.014 ml, 0.17 mmol) in acetone (5 ml) was stirred in a closed reaction tube at RT for 3 days. After concentrating the reaction, the residue was partitioned in ethyl acetate and water. The organic layer was dried (MgSO4) and concentrated to give crude product. The crude product was chromatographed (5% methanol in chloroform) on silica gel to give 8 mg of 7,9-dichloro-8-ethoxy-β-carboline.
EXAMPLE 40
7-chloro-8-fluoro-β-carboline trifluoroacetate
A solution of the product of example 31 (78 mg, 0.42 mmol) in 1M HCl (1 ml) was treated with N-chlorosuccinimide (115 mg, 0.9 mmol) portionwise and the resulting mixture was stirred at 60° C. to 70° C. for 3 h. The reaction was evaporated and the crude product purified by preparative HPLC using a C18-packed column and eluting with a gradient (5:95 to 50:50) of water-acetonitril (with 0.1% trifluoroacetic acid). The pure fractions with product were combined and lyophilized to provide 33 mg of the title compound.
EXAMPLE 41
1-hydroxy-7-trifluoromethyl-β-carboline and EXAMPLE 42 7-trifluoromethyl-β-carboline
A solution of 3-hydroxy-2-piperdone (96 mg, 0.83 mmol) in methylene chloride (5 ml) was treated with Dess Martin reagent (352 mg, 0.85 mmol) at RT and the resulting mixture was stirred for 1 h. After filtering the salts from the reaction, the ketone in solution was treated with 4-trifluoromethyl-phenyl-hydrazine (145 mg, 0.83 mmol). After 15 min, hexane (20 ml) was added and the hydrazone collected by filtration. This crude hydrazone was heated at 95° C. in formic acid (70%, 10 ml) for 1 h. The reaction was evaporated and the residue was chromatographed (ethyl acetate) on silica gel to give 60 mg of dihydro 1-hydroxy-7-trifluoromethyl-β-carboline.
A portion of dihydro 1-hydroxy-7-trifluoromethyl-β-carboline (6 mg) in xylenes (1 ml) was treated with Pd/C (10%, 7 mg) and the mixture heated at 50° C. for one week. The reaction was concentrated after filtering it through celite, and the residue was chromatographed (1:1 hexane-ethyl acetate) on silica gel to give 1 mg of 1-hydroxy-7-trifluoromethyl-β-carboline.
A portion of dihydro 1-hydroxy-7-trifluoromethyl-β-carboline (25 mg) in THF (1 ml) was treated with a solution of lithium aluminum hydride in THF (1M, 0.5 ml). The reaction was stirred at 60° C. for 6 h before quenching with water (5 ml) and extracting with ethyl acetate (3 times 10 ml). The combined organic layers were dried (MgSO4) and concentrated to provide tetrahydro 7-trifluoro-methyl-β-carboline. This material was taken up in xylenes (5 ml) and treated with Pd/C (10%, 15 mg). The mixture was stirred at 150° C. for 48 h before filtering through celite and concentrating. The residue was chromatographed (ethyl acetate) on silica gel to give 5 mg of 7-tri-fluoromethyl-β-carboline.
EXAMPLE 43
7-chloro-9-(methylamino)-β-carboline trifluoroacetate
A solution of the product of example 15 (50 mg, 0.23 mmol) in AcOH/methanol (1%, 3 ml) was treated with sodium cyanoborohydride (30 mg, 0.46 mmol) followed by formaldehyde (37%, 0.017 ml, 0.23 mmol). The reaction was stirred at RT for 36 h and then diluted with saturated NaHCO3 (9 ml). After stirring for 15 min, the crude product was filtered and washed with water. The crude product was purified as described in example 46. The pure fractions with product were combined and lyophilized to provide 13 mg of the title compound.
EXAMPLE 44
7-chloro-9-(dimethylamino)-β-carboline trifluoroacetate
A solution of the product of example 15 (50 mg, 0.23 mmol) in AcOH/methanol (1%, 3 ml) was treated with sodium cyanoborohydride (30 mg, 0.46 mmol) followed by formaldehyde (37%, 0.060 ml, 0.69 mmol). The reaction was stirred at RT for 36 h and then diluted with saturated NaHCO3 (9 ml). After stirring for 15 min, the crude product was filtered and washed with water. The crude product was purified as described in example 46. The pure fractions with product were combined and lyophilized to provide 40 mg of the title compound.
EXAMPLE 45
7-chloro-9-(methylsulfonylamino)-β-carboline trifluoroacetate
A solution of the product of example 15 (30 mg, 0.14 mmol) in pyridine (0.5 ml) was treated with methanesulfonyl chloride (0.024 ml, 0.30 mmol) in two portions over 30 h. The reaction was diluted with water (5 ml) and the crude product collected and washed with water (several times). The crude product was purified as described in example 46. The pure fractions with product were combined and lyophilized to provide 16 mg of the title compound.
EXAMPLE 46
7-chloro-9-(propylonylamino)-β-carboline trifluoroacetate
A solution of the product of example 15 (30 mg, 0.14 mmol) in pyridine (1.0 ml) was treated with propionyl chloride (0.015 ml, 0.17 mmol). After stirring at RT for 4 h, the reaction was diluted with water (9 ml) and saturated NaHCO3 (1 ml). The crude product was collected and washed with water (several times). The crude product was purified by preparative HPLC using a C18-packed column and eluting with a gradient (5:95 to 50:50) of water-acetonitril (with 0.1% trifluoroacetic acid). The pure fractions with product were combined and lyophilized to provide 21 mg of the title compound.
EXAMPLE 47
7-chloro-9-(benzoylamino)-β-carboline trifluoroacetate
A solution of the product of example 15 (30 mg, 0.14 mmol) in pyridine (1.0 ml) was treated with benzoyl chloride (0.020 ml, 0.17 mmol). After stirring at RT for 4 h, the reaction was diluted with water (9 ml) and saturated NaHCO3 (1 ml). The crude product was collected and washed with water (several times). The crude product was purified as described in example 46. The pure fractions with product were combined and lyophilized to provide 12 mg of 7-chloro-9-(benzoylamino)-β-carboline trifluoroacetate.
EXAMPLE 48
7-chloro-9-(Acetyl-methylamino)-β-carboline trifluoroacetate
A solution of the product of example 43 (19 mg, 0.082 mmol) in pyridine (0.40 ml) was treated with acetic anhydride (0.037 ml, 0.36 mmol) in two portions over 48 h. The reaction was subsequently concentrated to dryness and the residue coevaporated with AcOH under reduced pressure. The crude product was purified as described in example 46. The pure fractions with product were combined and lyophilized to provide 9 mg of the title compound.
EXAMPLE 49
7-chloro-9-(4-fluorobenzoylamino)-β-carboline trifluoroacetate
A solution of the product of example 15 (30 mg, 0.14 mmol) in pyridine (1.0 ml) was treated with 4-fluorobenzoyl chloride (0.018 ml, 0.17 mmol). After stirring at RT for 18 h, the reaction was diluted with water (10 ml). The crude product was purified as described in example 46. The pure fractions with product were combined and lyophilized to provide 13 mg of the title compound.
EXAMPLE 50
A cold (3° C. to 5° C.) solution of the product of example 15 (30 mg, 0.14 mmol) and pyridine (0.014 ml, 0.17 mmol) in THF (0.7 ml) was treated with phenyl chloroformate (0.018 ml, 0.145 mmol). After stirring at RT for 2 h, the reaction was partitioned in ethyl acetate and buffer (pH 7.2). The organic layer was dried (brine, Na2SO4) and concentrated to give 43 mg of phenyl carbamate.
To a solution of phenyl carbamate (30 mg, 0.089 mmol) in DMSO (0.5 ml) was added 2-methoxyethylamine (0.010 ml, 0.10 mmol). After stirring at RT for 30 min, the crude reaction mixture was purified as described in example 46. The pure fractions with product were combined and lyophilized to provide 21 mg of the title compound.
EXAMPLE 51
7-chloro-9-(methoxyacetylamino)-β-carboline trifluoroacetate
A solution of the product of example 15 (35 mg, 0.16 mmol) in pyridine (1.0 ml) was treated with methoxyacetyl chloride (0.016 ml, 0.18 mmol). After stirring at RT for 2 h, the reaction was diluted with water (10 ml). The crude product was purified as described in example 46. The pure fractions with product were combined and lyophilized to provide 32 mg of the title compound.
EXAMPLE 52
7-chloro-9-(3-methoxybenzoxylamino)-β-carboline trifluoroacetate
A solution of the product of example 15 (30 mg, 0.14 mmol) in pyridine (1.0 ml) was treated with m-anisoyl chloride (0.027 ml, 0.19 mmol) in two portions over 6 h. The reaction was subsequently diluted with water (10 ml) and the crude product was purified as described in example 46. The pure fractions with product were combined and lyophilized to provide 33 mg of the title compound.
EXAMPLE 53
7-chloro-9-(4-methoxybenzoxylamino)-β-carboline trifluoroacetate
A solution of the product of example 15 (30 mg, 0.14 mmol) in pyridine (1.0 ml) was treated with p-anisoyl chloride (37 mg, 0.22 mmol) in two portions over 24 h. The reaction was subsequently diluted with water (10 ml) and the crude product was purified as described in example 46. The pure fractions with product were combined and lyophilized to provide 24 mg of the title compound.
EXAMPLE 54
7-chloro-9-(methylcarbamylamino)-β-carboline trifluoroacetate
A solution of the product of example 15 (30 mg, 0.14 mmol) in pyridine (1.0 ml) was treated with p-anisoyl chloride (0.017 ml, 0.21 mmol) in two portions over 4 h. The reaction was subsequently diluted with water (10 ml) and the crude product was purified as described in example 46. The pure fractions with product were combined and lyophilized to provide 35 mg of the title compound.
EXAMPLE 55
7-chloro-9-(isovalerylamino)-β-carboline trifluoroacetate
A solution of the product of example 15 (35 mg, 0.16 mmol) in pyridine (1.0 ml) was treated with isovalerylchloride (0.033 ml, 0.28 mmol) in two portions over 24 h. The reaction was subsequently diluted with water (10 ml) and the crude product was purified as described in example 46. The pure fractions with product were combined and lyophilized to provide 52 mg of the title compound.
EXAMPLE 60
N-(6-Chloro-9H-β-carbolin-8-yl)-nicotinamide
To a solution of norharmane (2.0 g, 11.9 mmol) in water (89 ml) and 1M aqueous HCl (29.8 ml, 29.8 mmol) was added N-chlorosuccinimide (3.17 g, 23.8 mmol) portionwise. The resulting solution was stirred at RT for 6 h, and then at 0° C. to 5° C. for 12 h. The reaction was diluted with water (100 ml) and basified cautiously with solid K2CO3 (4.3 g). After stirring at RT for 1 h, the product was collected and washed with water. The crude product was refluxed in chloroform for 1 h and filtered after cooling to 15° C. to provide 2.05 g of 7-chloro-β-carboline.
A mixture 7-chloro-β-carboline (500 mg, 2.48 mmol) in concentrated nitric acid (20 ml) was stirred at RT for 22 h. The reaction mixture was carefully poured into cold (3° C. to 5° C.) water (50 ml), and after stirring for 2 h the precipitate was collected. The solid was suspended in saturated aqueous NaHCO3 (50 ml) and stirred at RT for 12 h. The product was filtered and washed with water to provide 550 mg of 7-chloro-9-nitro-β-carboline.
To a suspension of 7-chloro-9-nitro-β-carboline (548 mg, 2.22 mmol) in EtOH (14 ml) at 65° C. to 70° C. was added tin chloride dihydrate (2.5 g, 11.1 mmol). Thereafter, 6M aqueous HCl (14 ml) was added dropwise. The mixture was stirred at 70° C. to 80° C. for 3.5 h and then partitioned slowly into saturated aqueous NaHCO3 (150 ml) and EtOAc (100 ml). The aqueous phase was extracted (2 times) and the combined organic solutions dried (brine; NaSO4) and concentrated to give 484 mg of 9-amino-7-chloro-β-carboline.
To a cold (3-5° C.) solution of 9-amino-7-chloro-β-carboline (2.75 g, 12.7 mmol) in pyridine (150 ml) was added nicotinyl chloride hydrochloride (2.82 g, 15.8 mmol). The reaction was allowed to warm to RT and stirred for 20 h before diluting the reaction with water (100 ml) and 1M NaOH (25 ml). After stirring for 1 h at RT, the mixture was poured into water (200 ml). The mixture was allowed to stand for 1 h and the product was filtered to provide 3.80 g of the title compound after washing with water and drying under reduced pressure at RT.
EXAMPLE 68
N-(6-Chloro-7-methoxy-9H-β-carbolin-8-yl)-nicotinamide
A mixture of 6-methoxytryptamine (9.10 g, 47.8 mmol) in EtOAc (40 ml) and pH 4.5 NaOAc buffer (40 ml) was treated with glyoxalic acid hydrate (5.30, 57.6 mmol). The mixture was stirred vigorously for 2 days and then diluted with hexane (40 ml). The product was filtered and washed with water and (1:1) hexane-ethyl acetate. The crude product was crystallized from methanol after filtration of a hot methanol solution.
The crude product (11.5 g) from above in 6N HCl (100 ml) was treated 3 times with concentrated HCl (5.0 ml) every 15 min while refluxing. After refluxing for a total of 1 h, the reaction was concentrated to give a residue. This residue was slurried and sonicated with 10% Na2CO3 (300 ml) and filtered to give the free amine (7.20 g). The above amine was refluxed in xylenes (200 ml) and pyridine (100 ml) with 10% Pd/C (3 g) for 5 h. The hot reaction was filtered thru celite and the filtrate was concentrated to give 6.38 g of 8-methoxy-β-carboline.
To a mixture of 8-methoxy-β-carboline (1.0 g, 5 mmol) in THF (100 ml) was added N-chlorosuccinimide (0.70 g, 5.2 mmol). The reaction was stirred at RT for 4 h before concentrating and washing the residue with 1:1:1 mixture of 10% Na2CO3, hexane, and EtOAc (400 ml). The resulting residue was triturated with xylenes to provide 677 mg of 7-chloro-8-methoxy-β-carboline.
A solution of 7-chloro-8-methoxy-β-carboline (677 mg, 2.9 mmol) in trifluoroacetic acid (10 ml) was treated with NaNO3 (260 mg, 3.06 mmol). The reaction was stirred for 3 h at RT and then concentrated. The crude product was chromatographed on silica eluting with a 5% to 10% methanol in chloroform gradient to provide 463 mg of 7-chloro-8-methoxy-9-nitro-β-carboline.
A solution of 7-chloro-8-methoxy-9-nitro-β-carboline (460 mg, 1.66 mmol) in EtOH (25 ml) was treated with SnCl2-2H2O (450 mg, 2.00 mmol). The reaction was stirred for 5 h at 65° C. and then concentrated. The crude product was chromatographed on silica eluting with a 5 to 10% methanol in chloroform gradient to provide 410 mg of 7-chloro-8-methoxy-9-nitro-β-carboline.
A solution of 7-chloro-8-methoxy-9-nitro-β-carboline (21 mg, 0.085 mmol) in pyridine (1 ml) was treated with nicotinyl chloride hydrochloride (54 mg, 0.30 mmol) and 4-dimethylaminopyridine (5 mg). After stirring at 95° C.-100° C. for 7 h the reaction was concentrated, the residue slurried with 10% Na2CO3, and then chromatographed on silica eluting with a 5% to 10% methanol in chloroform gradient to provide 4.7 mg of the title compound.
EXAMPLE 82
N-(6-Chloro-9H-β-carbolin-8-yl)-3,4-difluoro-benzamide
To a cold (3° C.-5° C.) solution of 9-amino-7-chloro-β-carboline (2.50 g, 11.5 mmol, as prepared in example 60 above) in pyridine (130 ml) was added 3,4-diflourobenzoyl chloride (1.67 ml, 13.25 mmol). The reaction was allowed to warm to RT and stirred for 20 h before diluting the reaction with water (60 ml) and 1M NaOH (15 ml). After stirring for 3 h at RT, the pH of the mixture was adjusted to 8-9 with 1M HCl and then poured into water (250 ml). The mixture was allowed to stand for 30 min and the product was filtered to provide 3.95 g of the title compound after washing with water and drying under reduced pressure at 55° C.-60° C.
EXAMPLE 83
6-Chloro-N-(6-chloro-9H-β-carbolin-8-yl)-nicotinamide
To a cold (3-5° C.) solution of 9-amino-7-chloro-β-carboline (1.40 g, 6.45 mmol, as prepared in example 60 above) in pyridine (72 ml) was added 6-chloro-nicotinyl chloride (1.30 g, 7.42 mmol). The reaction was allowed to warm to RT and stirred for 16 h before diluting the reaction with water (60 ml) and 1M NaOH (8 ml). After stirring for 40 min at RT, the mixture was poured into water (200 ml). The mixture was allowed to stand for 30 min and the product was filtered to provide 2.20 g of the title compound after washing with water and drying under reduced pressure at RT.
The examples in Table 1 show the structures of certain prepared compounds, including those of the previous examples, and were prepared according to methods used in the previous examples.










TABLE 1





Example
Structure
Empirical formula
MS (M + H)


















1




C11H7BrN2
248


 


2




C13H9BrN2O
290


 


3




C11H7FN2
187


 


4




C14H15ClN2
211


 


5




C12H7N3
194


 


6




C11H8ClN3O2
214


 


7




C14H9F3N2O4
213


 


8




C11H7Br2ClN2
327


 


9




C11H6Cl2N2
238


 


10




C12H9BrN2O2S
326


 


11




C12H9BrN2
262


 


12




C11H7ClN2
204


 


13




C13H9ClN2O
246


 


14




C11H6ClN3O2
249


 


15




C11H8ClN3
219


 


16




C15H11ClF3N3O3
261


 


17




C16H14BrN3O2
361


 


18




C15H13ClN2O2
290


 


19




C13H11ClN2O
248


 


20




C13H9ClN2O2
262


 


21




C12H10N2O
199


 


22




C13H10ClN3O
261


 


23




C12H10N2O
199


 


24




C12H8Br2N2O
257


 


25




C18H20N2O3
313


 


26




C19H16N2O
289


 


27




C14H14N2O
227


 


28




C12H9BrN2
262


 


29




C14H12N2O2
241


 


30




C12H10N2O
199


 


31




C11H7FN2
187


 


32




C13H11BrN2O
292


 


33




C11H8N2O
185


 


34




C11H6ClFN2
222


 


35




C13H12N2O
213


 


36





348


 


37





382


 


38





254


 


39





282


 


40





222


 


41





253


 


42





237


 


43





347


 


44





361


 


45





411


 


46





389


 


47





437


 


48





388


 


49





454


 


50





448


 


51





404


 


52





467


 


53





467


 


54





391


 


55





416


 


56




C19H12ClF3N4O3
323


 


57




C18H17ClF3N3O3
302


 


58




C16H14Cl2N2O2
338


 


59




C16H13Cl2N3O3
367


 


60




C19H12ClF3N4O3
323


 


61




C20H12ClF4N3O3
340


 


62




C20H12ClF4N3O3
340


 


63




C12H9N3O3
244


 


64




C15H12Cl2N2O
308


 


65




C15H13Cl3N2O


 


66




C12H9ClN2O
234


 


67




C12H10ClN3O
249


 


68




C18H13ClN4O2
353


 


69




C21H14ClF3N4O3
349


 


70




C13H10Cl2N2O2
298


 


71




C20H16ClN3O3
383


 


72




C19H11ClN4O
348


 


73




C19H11ClN4O
348


 


74




C19H11ClF3N3O
391


 


75




C16H10ClN3O2
313


 


76




C16H10ClN3OS
329


 


77




C18H11ClF3N3O2
395


 


78




C20H20ClN5O
383


 


79




C15H9ClN4O2
314


 


80




C16H11ClN4O2
328


 


81




C18H12Cl2N2O
344


 


82




C18H10ClF2N3O
359


 


83




C17H10Cl2N4O
358


 


84




C14H12Cl2N2O
296


 


85




C15H14Cl2N2O
310


 


86




C17H12ClN3OS
343


 


87




C17H11ClN4O
323


 


88




C16H10ClN5O
323


 


89




C19H12ClN3O3
367


 


90




C20H16ClN3O2
366


 


91




C13H8ClN3O2
274


 


92




C16H14Cl2N2O
322


 


93




C17H19Cl2N3O
353


 


94




C12H8ClN3O3
279


 


95




C12H10ClN3O
248


 


96




C18H18Cl2N2O
350


 


97




C18H15Cl3N4O
337


 


98




C15H17Cl3N4O
290


 


99




C16H13ClN4O2
330


 


100




C19H14ClN3O2
353


 


101




C13H8Cl2N2O2
296


 


102




C15H10Cl2N2O3
338


 


103




C16H13ClN4O2
330


 


104




C17H11ClN4O2
340


 


105




C20H20ClN5O
383


 


106




C17H14ClN5O
341


 


107




C26H24ClN5O
359


 


108




C18H13ClN4O
338


 


109




C17H11ClN4O2
340


 


110




C17H13ClN4O2
342


 


111




C16H12ClN3O3
331


 


112




C17H11ClFN3O2S
377


 


113




C18H11BrClN3O
401


 


114




C19H13ClFN3O2
371


 


115




C17H13Cl3N4O2
339


 


116




C18H11Cl2N3O
357


 


117




C17H16ClN3O
314


 


118




C18H12Cl2N4O2
388


 


119




C16H11ClN4O3
343


 


120




C19H12ClF2N3O2
390


 


121




C17H12ClN5O
339









Pharmacological Examples

IkB-Kinase ELISA

The in-vitro assay for detecting and measuring inhibition activity against IκBα-kinase complex by candidate pharmacological agents employs a biotinylated polypeptide spanning both Ser32 and Ser36 of IκBα and a specific antibody binding only to the phosphorylated form of the polypeptide, being either monoclonal or polyclonal (such as the commercially-available anti-phospho-serine32 IκBα antibodies from New England Biolabs, Beverly, Mass., USA, cat. #9240). Once the antibody-phospho-polypeptide complex is formed, the complex can be detected by a variety of analytical methods utilizing such as radioactivity, luminescence, fluorescence or optical absorbance. For the use of the ELISA method, the complex can be immobilized either onto a biotin-binding plate (such as Neutravidin coated plate) and detected with a secondary antibody conjugated to HRP, or onto an antibody-binding plate (such as Protein-A coated plate) and detected with biotin-binding protein conjugated to HRP (such as Streptavidin-HRP). The level of activity can be correlated with a standard curve using synthetic phosphopeptides corresponding to the substrate polypeptide.
Experimental
IκBα kinase complex was prepared by first diluting 10 mL of HeLa S3 cell-extracts S100 fraction with 40 mL of 50 mM HEPES pH 7.5. Then, 40% ammonium sulfate was added and incubated on ice for 30 minutes. Precipitated pellet was redissolved with 5 mL of SEC buffer (50 mM HEPES pH 7.5, 1 mM DTT, 0.5 mM EDTA, 10 mM 2-glycerophosphate), clarified by centrifugation at 20,000×g for 15 min., and filtration through a 0.22 μm filter unit. Sample was loaded onto a 320-mL Superose-6 FPLC column (Amersham Pharmacia Biotech AB, Uppsala, Sweden) equilibrated with SEC buffer operated at 2 mL/min flow rate at 4° C. Fractions spanning the 670-kDa molecular-weight marker were pooled for activation. Kinase-containing pool was then activated by incubating with 100 nM MEKK1Δ, 250 μM MgATP,
10 mM MgCl2, 5 mM DTT, 10 mM 2-glycerophosphate, 2.5 μM Microcystin-LR, for 45 minutes at 37° C. Activated enzyme was stored at −80° C. until further use. Per well of a 96-well plate, compounds at various concentrations in 2 μL DMSO were pre-incubated for 30 minutes at 25° C. with 43 μL of activated enzyme diluted [1:25] with assay buffer (50 mM HEPES pH 7.5, 5 mM DTT, 10 mM MgCl2, 10 mM 2-glycerophosphate, 2.5 μM Microcystin-LR). Five microliters of peptide substrate (biotin-(CH2)6—DRHDSGLDSMKD-CONH2) at 200 μM stock solution was added to each well and incubated for 1 hour before quenching with 150 μL of 50 mM HEPES pH 7.5, 0.1% BSA, 50 mM EDTA, plus [1:200] antibody.
Quenched kinase reaction samples and phospho-peptide-calibration standards (biotin-(CH2)6—DRHDS[PO3]GLDSMKD-CONH2, serially diluted in assay buffer) at 100 μL per well were transferred to a Protein-A plate (Pierce Chemical Co., Rockford, Ill., USA) and incubated for 2 hours. with shaking. Following 3 washes with PBS, 100 μL of 0.5 μg/mL Streptavidin conjugated with HRP (horseradish peroxidase) diluted with 50 mM HEPES/0.1% BSA, was added for 30 minutes. After 5 washes with PBS,
100 μL TMB substrate (Kirkegaard & Perry Laboratories, Gaithersburg, Md., USA) was added and color development was stopped by adding 100 μL of 0.18 M H2SO4. Absorbance signals were recorded at 450 nm. Calibration-curve standards were fitted by linear regression using a 4-parameter dose-response equation. Based on this standard curve, levels of kinase activity were calculated in order to determine inhibition activity of candidate pharmacological agents.
Table 2 which follows shows the results.







TABLE 2







Kinase inhibition at a substance concentration of IC50 in μM











IkB-



Example
kinase



number
IC50














1
0.4



2
0.4



3
1



4
2.5



5
1



6
3



7
65



8
0.2



9
0.2



10
0.4



11
0.7



12
0.4



13
0.5



14
4



15
0.8



16
0.3



17
5



18
23



19
3



20
14



21
1.8



22
15



23
22



24
4.6



25
31



26
12



27
4.5



28
11



29
40



30
5.2



31
3.3



32
4.6



33
1.5



34
1



35
3.5



36
1.4



37
0.15



38
11



39
0.1



40
2



41
2.2



42
0.8



43
1



44
2



45
8.3



46
0.3



47
0.6



48
4



49
0.22



50
10



51
0.6



52
0.6



53
1.4



54
0.7



55
0.8



56
0.27



57
4.3



58
0.33



59
3.2



60
0.052



61
0.94



62
0.38



63
1.3



64
0.11



65
0.10



66
0.7



67
0.5



68
0.16



69
3.0



70
0.36



71
3.0



72
0.58



73
0.4



74
3.8



75
0.29



76
0.9



77
4.4



78
2.3



79
0.18



80
0.31



81
0.25



82
0.15



83
0.06



84
0.1



85
0.2



86
0.7



87
0.75



88
0.28



89
0.57



90
1.4



91
2.3



92
0.4



93
1.3



94
0.64



95
1.0



96
1.3



97
0.69



98
0.9



99
0.09



100
1.5



101
1.8



102
0.8



103
0.31



104
1.0



105
0.4



106
0.6



107
0.4



108
2.1



109
2.1



110
0.3



111
0.54



112
0.93



113
0.64



114
2.1



115
4.6



116
1.8



117
0.67



118
0.12



119
0.6



120
0.4










The compound according to example 121 shows a IC50 of 1.7.
Mouse Heterotopic Cardiac Transplant Model
In the mouse heterotopic cardiac transplant model across full histocompatibility barriers (BALB/c->C57BL/6 or B6/129), graft survival is typically limited to 7.3±0.4 days (mean±SD, n0 allografts) (see for example in Hancock W W, Sayegh M H, Zheng X G, Peach R, Linsley P S, Turka L A. Costimulatory function and expression of CD40-ligand, CD80 and CD86 or in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci (USA) 93, 1996, 13967-13972; and Hancock W W, Buelow R, Sayegh M H, Turka L A. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nature Med 4, 1998, 1392-1396).
The effects of oral administration of the compounds according to examples 49 and 60 were tested using 25 mg/kg/day for 14 days, starting at transplantation in said animal model. Whereas grafts in animals receiving the carrier, methyl-cellulose, rejected by 7 days (6.7±0.8), grafts in compound 49-treated mice survived around 15 days (15.3±0.6), and grafts in those given compound 60 survived for 20 days (20±1). Current immunosuppressive therapies used in transplantation have limited efficacy and/or considerable toxicity. Targeting of IkB-kinase with these agents significantly prolonged allograft survival without associated toxicity.

## Claims

1. A method for treating a patient experiencing at least one disorder involving an increased activity of IkB kinase, wherein the at least one disorder is allograft rejection, the method comprising administering to the patient an efficacious amount of at least one compound chosen from a compound of formula I



a stereoisomeric form of a compound of formula I, and a physiologically tolerable salt of a compound of formula I,
wherein B6, B7, B6 and B9 are ring atoms independently chosen from carbon atoms and nitrogen atoms and wherein B6, B7, B8 and B9 together are no more than two nitrogen atoms at the same time;
where the substituents R1, R2, R3, R4 and R8 may be independently chosen from
1. hydrogen atom,
2. halogen,
3. —OH,
4. —CN,
5. sulfo,
6. —NO2,
7. —NH2,
8. alkoxy,
9. substituted amino,
10. —NH—C(O)—R15, wherein R15 is a heterocycle having 5 to 7 ring atoms, an alkyl, an aryl, a substituted aryl or a substituted alkyl,
11. —COOH,
12. —O—R10, wherein R10 is alkyl, substituted alkyl or aryl,
13. —C(O)—R12, wherein R12 is alkyl, substituted alkyl or aryl,
14. —C(O)—O—R12, wherein R12 is alkyl, substituted alkyl or aryl,
15. aryl,
16. —O-aryl,
17. substituted aryl,
18. —O-substituted aryl,
19. alkyl,
20. substituted alkyl,
21. —CF3 and
22. —CF2—CF3,

provided that at least one of R1, R2, R3, R4 and R8 is not a hydrogen atom, and
provided that at least one of R1, R3, R4 and R8 is chosen from —NH—C(O)—R15, wherein R15 is an aryl or a substituted aryl;
R5 is 1. hydrogen atom,
2. alkyl,
3. alkyl radical, substituted at one or more positions by one or more of the radicals, halogen, amino or hydroxyl,
4. —C(O)—R9 or
5. —S(O)2—R9, in which
R9 is a) alkyl,
b) alkyl radical, substituted at one or more positions by one or more of the radicals, halogen, amino or hydroxyl,
c) aryl,
d) aryl radical, substituted at one or more positions by one or more of the radicals, halogen, amino, or hydroxyl,
e) —NH2,
f) alkoxy or
g) substituted amino, and



R6 and R7 may be independently chosen from
1. hydrogen atom,
2. halogen,
3. —OH,
4. methyl,
5. —O—(C1-C10)-alkyl, wherein alkyl is unsubstituted or mono- to tri-substituted by substituents independently chosen from
5.1 aryl,
5.2 halogen,
5.3 —NO2,
5.4 sulfo,
5.5 —COOH,
5.6 —NH2,
5.7 —O—(C1-C4)-alkyl and
5.8 —OH, and

6. —N(R13)2, wherein R13 is independently of one another chosen from hydrogen atom, aryl, —C(O)—(C1-C4)-alkyl and substituted aryl or alkyl, wherein said —C(O)—(C1-C4)-alkyl is unsubstituted or mono- or tri-substituted independently of one another as defined under 5.1 to 5.8, or
R13 together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms.